Airway Therapeutics secures $50m for Phase IIb/III zelpultide alfa trial

Airway Therapeutics has raised $50m to support its ongoing Phase IIb/III trial of zelpultide alfa to prevent BPD in very preterm infants. Airway Therapeutics expects to complete an interim analysis of the Phase IIb trial by the end of Q2 2027. The Phase IIb/III trial follows a Phase Ib study where the drug candidate showed favourable safety and tolerability profile. Credit: Sai Thaw Kyar / Shutterstock.com. Airway Therapeutics has raised $50m in new equity financing to support its ongoing Phase IIb/III clinical trial of zelpultide alfa for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants. The funds will…

Source: Clinical Trials Arena